
Vossius & Partner
Siebertstraße 4
81675 München

4SC AG
Deutschland
Our Ref: P2286 PCT BLN

Fig. 1






PCIR-1
w/o & w chloroquin
(primary screen)
Primary cells
hPBMC, B-cells,
dendritic cells (purified)
Murine whole blood/
splenocytes
Renca metastasis model
Filter 1
Filter 2
In vivo PD

Fig. 2

Fig. 3


IL6
rel . expression
50000
45000
40000
35000
30000
25000
20000
15000
10000
5000
0
IP-10
rel . expression
120
100
80
60
40
20
0
control
0.1% DMSO
TLR ago 1 10µM
TLR ago 1 1µM
TLR ago 1 0.1µM



Treatments: d1- 4 or d8 - 11
vehicle SMOLs
TOG d1-4
TOG d8-11
IMDZQ d1-4
IMDZQ d8-11
vehicle ODN
H1826 d1-4
H1826 d8-11
lung/ bw normalized to vehicle
baseline calculated from mean lung/ bw of 20 animals
30 mg/kg
20mg/kg
1mg/kg

Fig. 4A




Spleen
IL6
relative expression
Vehicle ODN
H2006
H2006-mC
Vehicle SMOLs
TOG
IMDZQ
1mg/kg
30mg/kg
20mg/kg
IP10
Blood
IP10

Fig. 4B

Fig. 5


Murine Renca renal carcinoma, lung weight at d28 (section)
no body weight loss
no significant intolerabilities
lung/bw ratio
normalized to naive* ctrl (set to 1)
2.00
1.75
1.50
1.25
1.00
***
*naive=no metastases, no treatment
Vehicle 10ml/kg SID i.v.
TLR ago 1 30mg/kg SID i.v.
TLR ago 2 20mg/kg SID i.v.